Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Investing Activities (2019 - 2021)

Historic Cash from Investing Activities for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q4 2021 value amounting to $43.2 million.

  • Black Diamond Therapeutics' Cash from Investing Activities rose 75045.13% to $43.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $130.6 million, marking a year-over-year increase of 14636.75%. This contributed to the annual value of $17.0 million for FY2024, which is 380.52% up from last year.
  • Black Diamond Therapeutics' Cash from Investing Activities amounted to $43.2 million in Q4 2021, which was up 75045.13% from $35.7 million recorded in Q3 2021.
  • In the past 5 years, Black Diamond Therapeutics' Cash from Investing Activities registered a high of $48.2 million during Q2 2021, and its lowest value of -$279.6 million during Q2 2020.
  • Its 3-year average for Cash from Investing Activities is -$13.7 million, with a median of $2000.0 in 2019.
  • Within the past 5 years, the most significant YoY rise in Black Diamond Therapeutics' Cash from Investing Activities was 4189090.91% (2020), while the steepest drop was 1398210000.0% (2020).
  • Over the past 3 years, Black Diamond Therapeutics' Cash from Investing Activities (Quarter) stood at -$2000.0 in 2019, then plummeted by 332300.0% to -$6.6 million in 2020, then soared by 750.45% to $43.2 million in 2021.
  • Its Cash from Investing Activities was $43.2 million in Q4 2021, compared to $35.7 million in Q3 2021 and $48.2 million in Q2 2021.